Boston Scientific Acquires Relievant Medsystems for $850M in Back Pain Ablation Tech Deal
Boston Scientific has announced its agreement to acquire Relievant Medsystems, a medical technology company specializing in treating chronic low back pain. The acquisition will expand Boston Scientific's neuromodulation portfolio and provide more treatment options for individuals with vertebrogenic pain. The transaction includes an upfront cash payment of $850 million, with additional contingent payments based on sales performance. The Intracept Intraosseous Nerve Ablation System developed by Relievant is the only FDA-cleared system for vertebrogenic pain and offers a minimally invasive outpatient procedure. The deal is expected to close in the first half of 2024.